Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003582 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
A Phase 1 study of Head and Neck Cancer and Carcinoma of Unknown Primary, sponsored by University of Miami.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00003582: Completed Phase 1 study of Head and Neck Cancer and Carcinoma of Unknown Primary, sponsored by University of Miami.
NCT00003582 is a Phase 1 study of Head and Neck Cancer and Carcinoma of Unknown Primary that has completed, run by University of Miami. The registered enrollment target is 36 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003582, a Phase 1 study of Head and Neck Cancer and Carcinoma of Unknown Primary, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of radiation therapy and chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy and amifostine in treating patients who have stage II, stage III, or stage IV head and neck cancer that cannot be surgically removed.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- PROCEDURE quality-of-life assessment
- DRUG fluorouracil
- DRUG amifostine trihydrate
Study Locations (1)
Florida
- Sylvester Cancer Center, University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1988-05 |
| Est. Completion | 1996-12 |
| Phase | Phase 1 |
What the finished NCT00003582 record still lists
NCT00003582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 5 interventions - of which cisplatin is the first listed.
NCT00003582 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00003582 about?
NCT00003582 is a clinical study titled "Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of radiation therapy and ...
What is the current status of trial NCT00003582?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 1988-05. Estimated completion is 1996-12.
What conditions does trial NCT00003582 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Carcinoma of Unknown Primary.
What interventions are being tested in trial NCT00003582?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), quality-of-life assessment (PROCEDURE), fluorouracil (DRUG), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00003582?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003582 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003582's enrollment target sits among peer trials
36 163rd of 250 higher than 87 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
RECRUITING · Phase 1
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia